UNSPSC 51452801: Ivermectin

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8883YP2R6D. European Medicines Agency schedules Ivermectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12089MIG. Ivermectin generally arises in the molecular formula C48H74O14.

The term IVERMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) IVERMECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ivermectin under HS 29419000 and SITC 54139. As of Q4 2014, IVERMECTIN remains the US FDA Preferred Term for this commodity. Ivermectin bears US NLM identifiers UMLS ID C0022322 and NCI Concept Code C61796.

UNSPSC 51452801 Ivermectin is a Commodity code that covers specific pharmaceutical products procured by state and local health agencies, though recent solicitation activity under this code shows limited direct alignment with ivermectin itself. State and local governments use this code tier to source pharmaceutical inventory through competitive bidding and cooperative purchasing vehicles, often structured as piggyback awards or direct IFB processes. The issuing bodies are primarily state health departments and county public health systems seeking to maintain pharmaceutical stockpiles for emergency preparedness, community health initiatives, and disease response. Procurement under related commodity codes in the pharmaceutical family typically involves quarterly or annual delivery schedules to designated health facilities, with vendors responsible for shipping, storage compliance, and maintenance of expiration dating protocols.

Recent activity under this code appears sparse and misaligned with ivermectin specifically. The Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (not ivermectin), totaling $2,999,999.11 over three years. Seminole County, Florida issued an IFB in June 2026 for Naloxone and drug deactivation systems — also outside the ivermectin scope. The mismatch between the code's nominal pharmaceutical category and the actual recent solicitations suggests that state and local procurement offices may tag pharmaceutical acquisitions inconsistently across the UNSPSC taxonomy, or that ivermectin demand under this specific code is currently inactive in publicly posted opportunities. Vendors should verify code alignment with individual issuing bodies before pursuing opportunities listed under this category.